Published by Josh White on 19th March 2025
(Sharecast News) - Hutchmed China, alongside Innovent Biologics, announced on Wednesday that the FRUSICA-2 phase two and three clinical trial evaluating the combination of fruquintinib and sintilimab as a second-line treatment for advanced renal cell carcinoma (RCC) in China had met its primary endpoint of progression-free survival.